Somatropin (Recombinant HGH)
Recombinant peptide hormone (191-amino-acid growth hormone)
Somatropin is recombinant human growth hormone, the 191-amino-acid hormone itself rather than a secretagogue. It is FDA-approved across several growth-hormone-deficiency and growth-failure indications and is the hormone that peptides such as sermorelin, CJC-1295, and the GHRPs prompt the pituitary to release. Because it is the native hormone, its effects and risks are comparatively well characterized.
Mechanism under study
Binds the growth hormone receptor to activate JAK2/STAT5 signaling, stimulating hepatic IGF-1 output alongside direct lipolytic and anabolic effects; it is the same hormone that GH-releasing peptides and analogs prompt the pituitary to secrete.
Research-reported dosing
Dosed in mg and IU (about 1 mg is 3 IU) and FDA-approved. Adult growth-hormone-deficiency regimens report roughly 0.2-0.4 mg/day subcutaneously titrated to IGF-1; pediatric growth indications are weight-based and higher. Reported, not recommended.
Some presentations are prefilled pens; a lyophilized 5 mg (about 15 IU) vial reconstituted with 2 mL bacteriostatic water yields 2.5 mg/mL (about 7.5 IU/mL). On a U-100 syringe 1 unit (0.01 mL) is about 25 mcg, or roughly 0.075 IU. Note the conversion of about 1 mg to 3 IU.
A 300 mcg dose ≈ 12 units (25 mcg per unit).
Open this mix in the calculator →Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
Somatropin (Recombinant HGH) FAQ
What is Somatropin (Recombinant HGH)?
Somatropin is recombinant human growth hormone, the 191-amino-acid hormone itself rather than a secretagogue. It is FDA-approved across several growth-hormone-deficiency and growth-failure indications and is the hormone that peptides such as sermorelin, CJC-1295, and the GHRPs prompt the pituitary to release. Because it is the native hormone, its effects and risks are comparatively well characterized.
What is the half-life of Somatropin (Recombinant HGH)?
Short after subcutaneous injection (elimination roughly 2-4 hours), while downstream IGF-1-mediated effects persist considerably longer.
What is the research-reported dosing for Somatropin (Recombinant HGH)?
Dosed in mg and IU (about 1 mg is 3 IU) and FDA-approved. Adult growth-hormone-deficiency regimens report roughly 0.2-0.4 mg/day subcutaneously titrated to IGF-1; pediatric growth indications are weight-based and higher. Reported, not recommended.
How is Somatropin (Recombinant HGH) reconstituted?
Some presentations are prefilled pens; a lyophilized 5 mg (about 15 IU) vial reconstituted with 2 mL bacteriostatic water yields 2.5 mg/mL (about 7.5 IU/mL). On a U-100 syringe 1 unit (0.01 mL) is about 25 mcg, or roughly 0.075 IU. Note the conversion of about 1 mg to 3 IU.
Is Somatropin (Recombinant HGH) FDA-approved?
Somatropin (Recombinant HGH) has an approved status in at least one context — see the overview above for the specific brand, region, and indication. Research-grade material sold separately is for laboratory use only.
References
Related peptides
Sermorelin
Growth-hormone-releasing hormone (GHRH) analog
A GHRH (1-29) analog — the shortest fully active fragment of GHRH — historically used clinically as a diagnostic agent and studied for supporting endogenous growth-hormone output.
CJC-1295
Growth-hormone-releasing hormone (GHRH) analog
A synthetic GHRH analog studied for stimulating growth-hormone release. Exists in a short-acting 'no-DAC' form (modified GRF 1-29) and a long-acting 'DAC' form.
Ipamorelin
Ghrelin-receptor agonist (GH secretagogue)
A selective ghrelin-receptor agonist studied for stimulating growth-hormone release with comparatively little effect on cortisol or prolactin, making it a frequently referenced 'clean' secretagogue.
IGF-1 LR3
Recombinant IGF-1 analog
A modified, long-acting analog of insulin-like growth factor 1 widely used as a research reagent in cell-culture and preclinical growth studies.
MK-677
Orally active non-peptide ghrelin receptor (GHS-R1a) agonist / growth hormone secretagogue
MK-677 (Ibutamoren) is an orally active growth hormone secretagogue that mimics ghrelin at the GHS-R1a receptor. Despite being grouped with research peptides, it is a small non-peptide molecule taken by mouth rather than injected. It remains investigational and is not an approved drug in the United States.